Rheumatoid Arthritis Completed Phase 2 Trials for Adalimumab (DB00051)

Also known as: RA / Rheumatic Arthritis / Arthritis, Rheumatoid / Arthritis,Rheumatoid / Rheumatoid Arthritis (RA) / Rheumatoid Arthritis(RA) / Arthritis, Rheumatoid (RA) / Systemic rheumatoid arthritis / Arthritis rheumatoid / Rheumatoid arthritis, unspecified / R arthritis / Rh arthritis / Atrophic arthritis

DBCOND0027961 (Rheumatoid Arthritis)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00550446A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid ArthritisTreatment
NCT02565810An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid ArthritisOther
NCT02833350Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)Treatment
NCT01225393A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid ArthritisTreatment
NCT00235833Adalimumab in Adult Japanese Subjects With Rheumatoid ArthritisTreatment
NCT01502423A Crossover Study of the Safety and Tolerability of Two Formulations of AdalimumabTreatment
NCT01561313Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab.Treatment
NCT02141997A Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to MethotrexateTreatment
NCT00595413Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)Treatment
NCT01752855Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With AdalimumabTreatment
NCT01712178A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and SafetyTreatment
NCT01373151Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to MethotrexateTreatment